通过PRC2介导的亡逃避是MDS/AML的治疗点,其中包括inv{3}/t{3}/t{3}和单体7的治疗点
Hiroyoshi Kunimoto1, Ayaka Miura1, Maiko Sagisaka2
1Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
HemaSphere
|July 14, 2025
概括
骨髓发育综合征 (MDS) 和急性骨髓白血病 (AML) 具有inv3 / t3 / 3和单体7是攻击性的. EZH2 抑制剂通过向 EVI1-PRC2-GADD45γ 轴诱导亡,揭示了治疗的脆弱性.
科学领域:
- 血液学 血液学 血液学
- 分子瘤学分子瘤学
- 癌症遗传学 癌症遗传学
背景情况:
- 骨髓发育综合征 (MDS) 和急性骨髓白血病 (AML) 具有inv3 / t3 / 3和单体7 (-7) 是一种侵略性的骨髓瘤恶性瘤.
- 这些特定的MDS/AML亚型的分子驱动因素和治疗脆弱性仍然不太清楚.
研究的目的:
- 调查分子病原体,并确定MDS/AML的治疗漏洞与inv{3}/t{3}/t{3}和-7{3}.
- 探索EZH2抑制剂在向这些侵袭性髓状细胞癌的有效性.
主要方法:
- 人类MDS/AML细胞的高通量药物查.
- 用CUT&Tag/RNA测序来分析分子相互作用.
- 功能性测试和体内小鼠模型来验证发现.
主要成果:
- 在MDS/AML中,EZH2抑制剂优先诱导apoptosis,具有inv3/t3和7.
- 通过PRC2的招募,EVI1激活了GADD45γ沉默,而EZH2的抑制则逆转了这种情况.
- 激活GADD45γ-p38-p53轴会在EZH2抑制的反应中调解亡.
结论:
- 具有inv3) / t3) 和 -7的MDS/AML表现出一种EVI1-PRC2介导的亡逃避机制,涉及GADD45γ抑制.
- 针对EZH2代表了这些高风险细胞遗传病变患者的有前途的治疗策略.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K


